Ocular Therapeutix successfully completed its Pre-NDA meeting with the FDA for AXPAXLI, confirming the submission plan for its wet AMD treatment. This keeps the company on track for a Q4 2026 NDA submission, potentially positioning AXPAXLI as the first TKI approved for wet AMD.
Ocular Therapeutix announced the successful completion of its Pre-NDA meeting with the FDA for AXPAXLI, an investigational product for wet age-related macular degeneration. This meeting confirmed the company's plan to submit the NDA based on SOL-1 Week 52 efficacy and safety data, interim SOL-R safety, and confirmatory evidence, keeping the submission on track for Q4 2026. This is a positive development for Ocular Therapeutix as it de-risks the regulatory pathway and maintains the timeline for a potential 2027 launch. For traders, this reinforces the long-term growth potential of OCUL, as AXPAXLI could be a significant revenue driver if approved, potentially being the first TKI for wet AMD. The short-term impact is likely moderate as the news confirms existing expectations, but it strengthens the investment thesis for the stock.